Tissue Factor and Tissue Factor Pathway Inhibitor As Key Regulators of Global Hemostasis: Measurement of Their Levels in Coagulation Assays

Overview

Journal Semin Thromb Hemost

Publisher Thieme

Specialties Cardiology & Vascular Diseases
Hematology

Date 2010 Oct 28

PMID 20978997

Citations 17

Authors

Raj S Kasthuri

Sam L Glover

Jeremiah Boles

Nigel Mackman

Affiliations

Soon will be listed here.

Abstract

The tissue factor (TF)/factor (F)VIIa complex is the primary initiator of coagulation in vivo. Tissue factor pathway inhibitor (TFPI) is the physiological inhibitor of the TF/FVIIa complex. Deficiencies of either TF or TFPI have not been reported in humans, and a complete absence of either of these two proteins in mice is embryonically lethal. To maintain normal hemostasis, levels of TF and TFPI need to be balanced. Increased levels of TF can overwhelm the inhibitory capacity of TFPI, resulting in thrombosis. Decreased levels of TF are associated with bleeding. Global assays of coagulation are defined as tests capable of evaluating all components of the clotting cascade that are present in plasma. In these tests the thrombogenic surface is either provided by platelets or exogenous phospholipids. Clotting assays currently used in clinical practice are not designed to measure endogenous levels of TF and TFPI. Therefore, there is a need to develop sensitive and specific assays for measuring levels of functional TF and TFPI in whole blood and plasma. These assays could be useful in patient management in many scenarios.

Citing Articles

Associations of tissue factor and tissue factor pathway inhibitor with organ dysfunctions in septic shock.

Lehner G, Tobiasch A, Perschinka F, Mayerhofer T, Waditzer M, Haller V Sci Rep. 2024; 14(1):14468.

PMID: 38914630 PMC: 11196691. DOI: 10.1038/s41598-024-65262-3.

Synergistic Power of Piceatannol and/or Vitamin D in Bleomycin-Induced Pulmonary Fibrosis In Vivo: A Preliminary Study.

Ezz Eldeen N, Moustafa Y, Alwaili M, Alrehaili A, Khodeer D Biomedicines. 2023; 11(10).

PMID: 37893021 PMC: 10604873. DOI: 10.3390/biomedicines11102647.

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.

Englisch C, Moik F, Thaler J, Koder S, Mackman N, Preusser M Haematologica. 2023; 109(4):1128-1136.

PMID: 37822244 PMC: 10985431. DOI: 10.3324/haematol.2023.283581.

Coagulopathy of Dengue and COVID-19: Clinical Considerations.

Islam A, Cockcroft C, Elshazly S, Ahmed J, Joyce K, Mahfuz H Trop Med Infect Dis. 2022; 7(9).

PMID: 36136621 PMC: 9500638. DOI: 10.3390/tropicalmed7090210.

The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis.

Protty M, Jenkins P, Collins P, ODonnell V Open Biol. 2022; 12(4):210318.

PMID: 35440201 PMC: 9019515. DOI: 10.1098/rsob.210318.

References

Aras O, Shet A, Bach R, Hysjulien J, Slungaard A, Hebbel R . Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood. 2004; 103(12):4545-53. DOI: 10.1182/blood-2003-03-0713. View

Futers T, Moia M, Mannucci P, Grant P, Ariens R . Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol. 2001; 113(2):537-43. DOI: 10.1046/j.1365-2141.2001.02752.x. View

Luther T, Flossel C, Hietschhold V, Koslowski R, Muller M . Flow cytometric analysis of tissue factor (TF) expression on stimulated monocytes--comparison to procoagulant activity of mononuclear blood cells. Blut. 1990; 61(6):375-8. DOI: 10.1007/BF01738553. View

Tilley R, Mackman N . Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost. 2006; 32(1):5-10. DOI: 10.1055/s-2006-933335. View

Censarek P, Bobbe A, Grandoch M, Schror K, Weber A . Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost. 2007; 97(1):11-4. View

Hoke M, Kyrle P, Minar E, Bialonzcyk C, Hirschl M, Schneider B . Tissue factor pathway inhibitor and the risk of recurrent venous thromboembolism. Thromb Haemost. 2005; 94(4):787-90. DOI: 10.1160/TH05-06-0412. View

Koch L, Hofer S, Weigand M, Frommhold D, Poeschl J . Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thromb Res. 2009; 124(4):463-7. DOI: 10.1016/j.thromres.2009.05.002. View

Gross P, Weitz J . New antithrombotic drugs. Clin Pharmacol Ther. 2009; 86(2):139-46. DOI: 10.1038/clpt.2009.98. View

Howard E, Becker K, Rusconi C, Becker R . Factor IXa inhibitors as novel anticoagulants. Arterioscler Thromb Vasc Biol. 2007; 27(4):722-7. DOI: 10.1161/01.ATV.0000259363.91070.f1. View

10.

Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina R, Sandset P . Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003; 101(11):4387-92. DOI: 10.1182/blood-2002-10-3188. View

11.

Duering C, Kosch A, Langer C, Thedieck S, Nowak-Gottl U . Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke. Thromb Haemost. 2004; 92(4):707-12. DOI: 10.1160/TH04-05-0293. View

12.

Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T . Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun. 2001; 281(2):603-9. DOI: 10.1006/bbrc.2001.4399. View

13.

Khorana A, Francis C, Menzies K, Wang J, Hyrien O, Hathcock J . Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6(11):1983-5. PMC: 2848502. DOI: 10.1111/j.1538-7836.2008.03156.x. View

14.

Ollivier V, Wang J, Manly D, Machlus K, Wolberg A, Jandrot-Perrus M . Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res. 2009; 125(1):90-6. PMC: 2826585. DOI: 10.1016/j.thromres.2009.03.003. View

15.

Haubold K, Rink M, Spath B, Friedrich M, Chun F, Marx G . Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009; 101(6):1147-55. View

16.

Mackman N, Taubman M . Tissue factor: past, present, and future. Arterioscler Thromb Vasc Biol. 2009; 29(12):1986-8. PMC: 2848486. DOI: 10.1161/ATVBAHA.109.198929. View

17.

Tesselaar M, Romijn F, Van der Linden I, Prins F, Bertina R, Osanto S . Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2006; 5(3):520-7. DOI: 10.1111/j.1538-7836.2007.02369.x. View

18.

Kasthuri R, Taubman M, Mackman N . Role of tissue factor in cancer. J Clin Oncol. 2009; 27(29):4834-8. PMC: 2764391. DOI: 10.1200/JCO.2009.22.6324. View

19.

Bladbjerg E, Madsen J, Kristensen S, Abrahamsen B, Brixen K, Mosekilde L . Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study. J Thromb Haemost. 2003; 1(6):1208-14. DOI: 10.1046/j.1538-7836.2003.00281.x. View

20.

Bogdanov V, Cimmino G, Tardos J, Tunstead J, Badimon J . Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay. J Thromb Haemost. 2009; 7(5):894-7. DOI: 10.1111/j.1538-7836.2009.03315.x. View